| 名稱 | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat |
| 型號 | CBP74105 |
| 報價 |  |
| 特點(diǎn) | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat,母細(xì)胞：Jurkat，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 國內(nèi)研究者Cell Research：韓春雨NgAgo有效
- 研究發(fā)現(xiàn)氣候可能決定人的鼻子形狀
- 腫瘤細(xì)胞到底是如何“轉(zhuǎn)移”的呢？
- 第四代ALK激酶抑制劑篩選模型
- 羅氏乳腺癌新藥獲英國NICE批準(zhǔn)用于HER2乳腺癌新輔助治療
- 5月是黑色素瘤意識月，盤點(diǎn)黑色素瘤研究進(jìn)展
- NIPT標(biāo)準(zhǔn)品-助力無創(chuàng)產(chǎn)前檢測
- 人結(jié)腸癌細(xì)胞株的細(xì)胞形態(tài)是不太規(guī)則的三角形
- 喝熱茶或使食管癌風(fēng)險增加5倍
- BTLA細(xì)胞篩選模型簡介
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74105ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat
- 詳細(xì)內(nèi)容
| CBP74105 | |
| I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. | |
| II. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIa_NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | N/A |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
| Storage: | Liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| III. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| IV.Representative Data | |
| |
Figure 1：Dose response of Rituximab in ADCP Bioassay Effector Cell FcγRIa/NFAT Reporter-Jurkat (C11)，the EC50 was 1.94ng/ml. | |
